Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)

Trial Profile

Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Eosinophilia; Nasal polyps; Sinusitis
  • Focus Therapeutic Use
  • Sponsors Knopp Biosciences
  • Most Recent Events

    • 09 Jul 2019 According to an Knopp Biosciences media release, an overview data of the eosinophil-lowering effects of dexpramipexole observed in this study will be presented at the 11th Biennial Symposium of the International Eosinophil Society.
    • 07 Mar 2017 According to a Knopp Biosciences media release, results from this study were presented at 2017 American Academy of Allergy and Immunology (AAAAI).
    • 07 Mar 2017 Results published in the Knopp Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top